Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel B Costa

Showing results (121-130 of 175) with videos related to

Pageof 18
Sort By:
Lung Cancer (Amsterdam, Netherlands)|March 14, 2017
Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomesPaul A VanderLaan, Deepa Rangachari, Susan M Mockus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2020
Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung AdenocarcinomasSusan E Jorge, Antonio R Lucena-Araujo, Hiroyuki Yasuda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 30, 2018
EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung AdenocarcinomasSusan E Jorge, Antonio R Lucena-Araujo, Hiroyuki Yasuda, et al.
Lung Cancer (Amsterdam, Netherlands)|February 8, 2018
Tumor biomarker testing in non-small-cell lung cancer: A decade of changePaul A VanderLaan, Deepa Rangachari, Adnan Majid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2012
The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutationsStephanie Heon, Beow Y Yeap, Neal I Lindeman, et al.
Cancer Treatment Communications|November 25, 2015
Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practiceDeepa Rangachari, Paul A VanderLaan, Xiuning Le, et al.
Lung Cancer (Amsterdam, Netherlands)|February 17, 2015
Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancersDeepa Rangachari, Norihiro Yamaguchi, Paul A VanderLaan, et al.
Lung Cancer (Amsterdam, Netherlands)|February 22, 2015
De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitorsXiuning Le, Neelam V Desai, Adnan Majid, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 5, 2019
EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical SamplesDeepa Rangachari, Ciric To, Jason E Shpilsky, et al.
Lung Cancer (Amsterdam, Netherlands)|February 12, 2014
Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancerPaul A Vanderlaan, Norihiro Yamaguchi, Erik Folch, et al.
Pageof 18

Showing results (121-130 of 175) with videos related to

Sort By:
Pageof 18
Lung Cancer (Amsterdam, Netherlands)|March 14, 2017
Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomesPaul A VanderLaan, Deepa Rangachari, Susan M Mockus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2020
Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung AdenocarcinomasSusan E Jorge, Antonio R Lucena-Araujo, Hiroyuki Yasuda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 30, 2018
EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung AdenocarcinomasSusan E Jorge, Antonio R Lucena-Araujo, Hiroyuki Yasuda, et al.
Lung Cancer (Amsterdam, Netherlands)|February 8, 2018
Tumor biomarker testing in non-small-cell lung cancer: A decade of changePaul A VanderLaan, Deepa Rangachari, Adnan Majid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2012
The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutationsStephanie Heon, Beow Y Yeap, Neal I Lindeman, et al.
Cancer Treatment Communications|November 25, 2015
Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practiceDeepa Rangachari, Paul A VanderLaan, Xiuning Le, et al.
Lung Cancer (Amsterdam, Netherlands)|February 17, 2015
Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancersDeepa Rangachari, Norihiro Yamaguchi, Paul A VanderLaan, et al.
Lung Cancer (Amsterdam, Netherlands)|February 22, 2015
De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitorsXiuning Le, Neelam V Desai, Adnan Majid, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 5, 2019
EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical SamplesDeepa Rangachari, Ciric To, Jason E Shpilsky, et al.
Lung Cancer (Amsterdam, Netherlands)|February 12, 2014
Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancerPaul A Vanderlaan, Norihiro Yamaguchi, Erik Folch, et al.
Pageof 18